新材料,石油炼制,石油化工,精细化工,生物医药

化学生物学、药物化学

生物活性;大小调控;基因组编辑;放线菌;药物研发;靶向治疗;再生重塑;肝脏发育;靶点验证;选择分离

Cancer Genomics;Breast Cancer;Multidisciplinary;Humanities And Social Sciences;Science;Gene Set Enrichment Analysis;General;Tumor Evolution;Innate Immunity;Porous Silicon

1. Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells
Mathew J. Garnett; Elena J. Edelman; Sonja J. Heidorn; Chris D. Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I. Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy J. Milano
Nature, 2012

2. GDSCTools for Mining Pharmacogenomic Interactions in Cancer
Francesco Iorio; Theo A. Knijnenburg; Daniel J. Vis; Graham R. Bignell; Michael P. Menden; Michael Schubert; Nanne Aben; Emanuel Goncalves; Syd Barthorpe; Howard Lightfoot; Thomas Cokelaer; Patricia Greninger; Ewald van Dyk; Han Chang; Heshani de Silva
Clinical Cancer Research, 2017

3. Targeting Bcr–Abl by Combining Allosteric with ATP-binding-site Inhibitors
Jianming Zhang; Francisco J. Adrián; Wolfgang Jahnke; Sandra W. Cowan-Jacob; Allen G. Li; Roxana E. Iacob; Taebo Sim; John Powers; Christine Dierks; Fangxian Sun; Gui-Rong Guo; Qiang Ding; Barun Okram; Yongmun Choi; Amy Wojciechowski
Nature, 2010

4. Oridonin is a Covalent NLRP3 Inhibitor with Strong Anti-Inflammasome Activity
Hongbin He; Hua Jiang; Yun Chen; Jin Ye; Aoli Wang; Chao Wang; Qingsong Liu; Gaolin Liang; Xianming Deng; Wei Jiang; Rongbin Zhou
Nature Communications, 2018

5. Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer.
Peter S. Hammerman; Martin L. Sos; Alex H. Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E. Brace; Brittany A. Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R. Simard
CANCER DISCOVERY, 2011

6. Identification of a Selective and Direct NLRP3 Inhibitor to Treat Inflammatory Disorders
Hua Jiang; Hongbin He; Yun Chen; Wei Huang; Jinbo Cheng; Jin Ye; Aoli Wang; Jinhui Tao; Chao Wang; Qingsong Liu; Tengchuan Jin; Wei Jiang; Xianming Deng; Rongbin Zhou
JOURNAL OF EXPERIMENTAL MEDICINE, 2017

7. Characterization of a Selective Inhibitor of the Parkinson’s Disease Kinase LRRK2
Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray
Nature Chemical Biology, 2011

8. Pharmacological Targeting of Kinases MST1 and MST2 Augments Tissue Repair and Regeneration.
Fuqin Fan; Zhixiang He; Lu-Lu Kong; Qinghua Chen; Quan Yuan; Shihao Zhang; Jinjin Ye; Hao Liu; Xiufeng Sun; Jing Geng; Lunzhi Yuan; Lixin Hong; Chen Xiao; Weiji Zhang; Xihuan Sun
Science Translational Medicine, 2016

9. Low-dose Metformin Targets the Lysosomal AMPK Pathway Through PEN2
Teng Ma; Xiao Tian; Baoding Zhang; Mengqi Li; Yu Wang; Chunyan Yang; Jianfeng Wu; Xiaoyan Wei; Qi Qu; Yaxin Yu; Shating Long; Jin-Wei Feng; Chun Li; Cixiong Zhang; Changchuan Xie
Nature, 2022

10. Integration of Hippo Signalling and the Unfolded Protein Response to Restrain Liver Overgrowth and Tumorigenesis
Hongtan Wu; Luyao Wei; Fuqin Fan; Suyuan Ji; Shihao Zhang; Jing Geng; Lixin Hong; Xin Fan; Qinghua Chen; Jing Tian; Mingting Jiang; Xiufeng Sun; Changnan Jin; Zhen-Yu Yin; Qingxu Liu
Nature Communications, 2015

1. 一种精氨酸甲基转移酶PRMT1抑制剂及其应用
厦门大学
邓贤明; 张保锭; 李文娟; 刘文; 林怡安
公开日期: 2025-03-11 申请日期: 2022-09-16 公开号: CN115813928B

2. SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE
Dana-Farber Cancer Institute Inc.; The Scripps Research Institute
Nathanael S. GRAY; Jianming ZHANG; Barun OKRAM; Xianming DENG; Jae Won CHANG; Amy WOJCIECHOWSKI
公开日期: 2024-05-16 申请日期: 2024-01-24 公开号: US20240158403A1

3. 苯并二噁烷类化合物、其制备方法与应用
南京红云生物科技有限公司
邓贤明; 黄伟; 吴振华; 云彩红; 张建明; 黄鑫
公开日期: 2024-03-29 申请日期: 2022-08-05 公开号: CN117794923A

4. Small molecule myristate inhibitors of Bcr-abl and methods of use
Dana-Farber Cancer Institute Inc.; The Scripps Research Institute
Nathanael S. Gray; Jianming Zhang; Barun Okram; Xianming Deng; Jae Won Chang; Amy Wojciechowski
公开日期: 2024-03-19 申请日期: 2022-01-12 公开号: US11932646B2

5. 噻唑啉酮杂环化合物、其制备方法以及药用组合物
中国科学技术大学
周荣斌; 陈云; 邓贤明
公开日期: 2024-02-23 申请日期: 2017-06-26 公开号: CN111303070B

6. Type II raf kinase inhibitors
Dana-Farber Cancer Institute Inc.
Hwan Geun Choi; Nathanael S. Gray; Jianming Zhang; Xianming Deng
公开日期: 2023-11-28 申请日期: 2020-06-04 公开号: US11826365B2

7. EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF
HONGYUN BIOTECH CO. LTD.
Xianming DENG; Wei HUANG; Zhenhua WU; Yachuang WU; Caihong YUN; Jianming ZHANG; Xin HUANG
公开日期: 2023-10-05 申请日期: 2021-05-24 公开号: US20230310428A1

8. ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
Hongyun Biotech Co. Ltd.
Wei Huang; Zhenhua Wu; Caihong Yun; Xin Huang; Xianming Deng; Yachuang Wu; Jianming Zhang
公开日期: 2023-07-06 申请日期: 2021-06-07 公开号: US20230212147A1

9. ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
Hongyun Biotech Co. Ltd.
DENG Xianming; HUANG Wei; WU Zhenhua; YUN Caihong; WU Yachuang; ZHANG Jianming; HUANG Xin
公开日期: 2023-04-19 申请日期: 2021-06-07 公开号: EP4166553A1

10. 取代喹唑啉类化合物、其制备方法、药物组合及应用
南京红云生物科技有限公司
邓贤明; 黄伟; 盛伸; 云彩红; 张建明; 黄鑫
公开日期: 2023-04-04 申请日期: 2021-06-18 公开号: CN115916759A

11. 烯基嘧啶类化合物、其制备方法与应用
南京红云生物科技有限公司
邓贤明; 黄伟; 吴振华; 吴亚闯; 云彩红; 张建明; 黄鑫
公开日期: 2023-02-03 申请日期: 2021-06-07 公开号: CN115697996A

12. STK19 inhibitors for treatment of cancer
TRUSTEES OF BOSTON UNIVERSITY; XIAMEN UNIVERSITY
Rutao Cui; Chengqian Yin; Xianming Deng; Ting Zhang
公开日期: 2023-01-03 申请日期: 2019-12-20 公开号: US11542240B2

13. 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
厦门大学
邓贤明; 黄伟; 孙细欢; 张婷; 何志祥; 刘琰; 吴昕瑞; 张保锭; 李小阳; 张婧芳; 陈云; 李莉; 徐庆妍; 胡志钰
公开日期: 2022-12-27 申请日期: 2018-08-03 公开号: CN110997669B

14. 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
上海交通大学医学院附属瑞金医院; 厦门大学
任瑞宝; 邓贤明; 吴敏; 张婷; 焦波; 康巧凤; 黄伟
公开日期: 2022-12-06 申请日期: 2018-11-02 公开号: CN111295387B

15. 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
厦门大学
邓贤明; 黄伟; 孙细欢; 张婷; 何志祥; 刘琰; 吴昕瑞; 张保锭; 李小阳; 张婧芳; 陈云; 李莉; 徐庆妍; 胡志钰
公开日期: 2022-09-16 申请日期: 2018-08-03 公开号: CN115057855A

16. SPAK kinase inhibitors as neuroprotective agents
United States Government as represented by the Department of Veterans Affairs; The University of Pittsburgh—of the Commonwealth of Higher Education; Xiamen University; University of Exeter
Dandan Sun; Xianming Deng; Jinwei Zhang; Mohammad Iqbal Hossain Bhuiyan; Bradley J. Molyneaux
公开日期: 2022-08-16 申请日期: 2021-02-16 公开号: US11414379B2

17. Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
Xiamen University
Xianming Deng; Wei Huang; Xihuan Sun; Ting Zhang; Zhixiang He; Yan Liu; Xinrui Wu; Baoding Zhang; Xiaoyang Li; Jingfang Zhang; Yun Chen; Li Li; Qingyan Xu; Zhiyu Hu
公开日期: 2022-06-07 申请日期: 2018-08-03 公开号: US11352354B2

18. SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE
Dana-Farber Cancer Institute Inc.; The Scripps Research Institute
Jianming ZHANG; Jae Won CHANG; Nathanael S. GRAY; Xianming DENG; Barun OKRAM; Amy WOJCIECHOWSKI
公开日期: 2022-05-05 申请日期: 2022-01-12 公开号: US20220135573A1

19. 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
厦门大学
邓贤明; 张保锭; 刘双; 董超; 孙细欢; 黄晓星; 邓舟; 李云展; 鲁岳; 李莉; 胡志钰
公开日期: 2022-04-08 申请日期: 2016-08-09 公开号: CN107698603B

20. EGFR抑制剂、其制备方法及用途
南京红云生物科技有限公司
邓贤明; 黄伟; 吴振华; 吴亚闯; 云彩红; 张建明; 黄鑫
公开日期: 2021-11-30 申请日期: 2021-05-13 公开号: CN113717156A

1. 基于海洋微生物的靶向抗肿瘤药物研究
立项时间: 2015-2018 项目经费：2560000

2. 靶向抗肿瘤药物学
立项时间: 2015-2017 项目经费：1000000

3. Extending bicyclomycin treatment of multi-drug resistant Gram-negative pathogens
立项时间: 2016-2019 项目经费：490718

4. 双环霉素杀灭多重耐药革兰氏阴性菌的机理和应用研究
立项时间: 2016-2019 项目经费：2508500

5. 基于激酶LRRK2为靶标的帕金森症靶向药物研究
立项时间: 2013-2016 项目经费：800000

6. 靶向非小细胞肺癌相关激酶ALK蛋白降解药物的发现和作用机制研究
立项时间: 2023

7. 化学新前沿学术研讨会
立项时间: 2019-2019

8. 靶向宿主脂激酶PIKfyve的抗冠状病毒药物发现
立项时间: 2021

技术咨询